Butyrate reportedly enhances the therapeutic efficacy of anti-PD-1 agents by increasing CD4+ and CD8+ T-cell infiltration in the TME in tumor-bearing mice humanized with intestinal microbes from colorectal cancer (CRC) patients (132). Here, CD8A is linked to neoplasm.